Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of a supply shortage of Aimovig on people who experience migraines.

The Department is aware of a recent short term supply issue with one strength of Aimovig. We worked with NHS England, the Medicines and Healthcare products Regulatory Agency, and the devolved administrations to expedite resupply and have confirmed that stock is now available for patients to access.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues.

While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise, to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, and use of Serious Shortage Protocols. In addition, we will issue communications to the National Health Service, which provides management advice and information on the issue to healthcare professionals, including pharmacists, so they can advise and support their patients.